Generics & Biosimilars | Association for Accessible Medicines
  • ""
    Nothing to See Here
    Brand-name drug companies claim that without USMCA, there's no market for biologics in Mexico. Fact: The world's largest pharmaceutical companies launched their top-selling biologics in Mexico.
  • #DoesntAddUp
    If generic prescription drug prices are falling each year, why are consumer costs for prescription drugs rising?
  • ""
    The Case for Competition
    Now available: AAM's full 2019 Generic Drug & Biosimilars Access & Savings in the U.S. Report
  • Access Denied: Why New Generics Are Not Reaching America's Seniors
    New White Paper: Access Denied
    AAM's "Access Denied" white paper highlights new data on the treatment of generic medicines in Medicare Part D, resulting in patients paying more for their medicines even when lower-priced FDA-approved generics and biosimilars are available.
  • ""
    How Much Did Your State Save?
    Take a deeper look at state-by-state generic drug savings from the 2019 Generic Drug and Biosimilars Access & Savings in the U.S. report.
  • NAFTA 2.0: Obstacles to More Affordable Medicines for Americans
    NAFTA 2.0: Obstacles to More Affordable Medicines
    The U.S.-Mexico-Canada Agreement (USMCA) or "NAFTA 2.0" contains obstacles to more affordable meds for Americans. There is still time to #FixUSMCA to put America’s patient first!

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.